Cutting-Edge medtech startups unveiled for accelerator program

MedTech & Diagnostics News: The largest accelerator of medical technology companies, revealed the selected participants for its highly anticipated annual Asia Pacific Accelerator program. This exciting development promises innovative advancements in medtech throughout the region.

The MedTech Innovator Asia Pacific program offers unparalleled opportunities for best-in-class startups to collaborate with influential investors, visionary business leaders, and skilled professionals in the medtech industry. By joining forces, they aim to expedite the commercialisation of life-changing technologies across the Asia Pacific region. As an added incentive, the companies forming the 2023 cohort will compete for an impressive pool of up to US$ 300,000 in cash prizes and esteemed awards.

Paul Grand, CEO of MedTech Innovator, expressed his enthusiasm for the program, stating, “As the world’s largest accelerator of medtech companies, MedTech Innovator established the Asia Pacific Program in 2019 because of the incredible innovation in the region. We look forward to working with our partners to support this year’s cohort of companies and to help them advance their technologies.”

MedTech Innovator’s Asia Pacific program has garnered immense support from industry giants and sponsors, including Johnson & Johnson, Olympus, Teleflex, Siemens Healthineers, B Braun Medical, Cambridge Consultants, JABIL Healthcare, and Enterprise Singapore. These influential organisations are committed to fostering innovation and driving the future of healthcare.

This year, the program witnessed an overwhelming response, with over 400 ambitious companies vying for a chance to be part of the Asia Pacific Accelerator. Following a rigorous selection process, 60 companies were granted the opportunity to pitch their ideas. Ultimately, 24 outstanding startups were chosen to join the prestigious 2023 cohort, propelling them one step closer to realising their revolutionary visions.

The grand culmination of this remarkable journey will take place at APACMed’s Medtech Forum 2023 in Singapore, where four startups from the 2023 Asia Pacific cohort will advance to compete in the Grand Finals. Esteemed by prominent figures in the healthcare industry, leading healthcare providers, and visionary investors from across the region, the MedTech Forum will also serve as a platform to showcase the innovative solutions presented by all 24 Accelerator cohort companies. The audience’s voice will reign supreme as they determine the winner, who will not only walk away with a prestigious non-dilutive cash prize but also be crowned the coveted 2023 MedTech Innovator Asia Pacific Winner.

In an exciting first, MedTech Innovator Asia Pacific’s 2023 cohort includes four standout companies chosen from the inaugural Olympus Asia Pacific Innovation Program (OAIP). This specialised program focuses on developing minimally invasive care and pioneering approaches to detect, monitor, and treat a wide range of conditions and diseases. The fortunate winner of the Olympus Asia Pacific Innovation Program will be awarded an esteemed grant funding of US$ 75,000 and the exclusive opportunity to engage in a mentorship program with key thought leaders from within Olympus.

The 24 visionary companies that have secured their place in the esteemed 2023 MedTech Innovator Asia Pacific Accelerator are:

1. Accuster Technologies (India)
2. Astron Medtech (US)
3. Biotome (Australia)
4. Flexperc Medical (US)
5. Gbrain (South Korea)
6. GenLight Medical (China)
7. Healium Medical (Israel)
8. Jdot (Changzhou) Medical Technology (China)
9. Kinexcs (Singapore)
10. Lifespans (Hong Kong, China)
11. Medipixel (South Korea)
12. MedySapiens (South Korea)
13. Module Innovations (India)
14. Neurowyzr (Singapore)
15. NICE Surgical Solutions (Singapore)
16. Ossfila Technology (Hong Kong, China)
17. PrimaNova Technologies (Hong Kong, China)
18. Thrixen (Singapore)
19. Vivo Surgical (Singapore)
20. Weinnovate Biosolutions (India)

The esteemed shortlisted companies for the Olympus Asia Pacific Innovation Program (OAIP) are:

1. BioCliq (India)
2. NDR Medical (Singapore)
3. Sonire Therapeutics (Japan)
4. Vesica Corporation (US)

With the stage set for ground-breaking advancements in medtech, the Asia Pacific region eagerly awaits the transformative ideas and solutions that these 24 visionary companies will bring to the table. As they embark on their accelerator journey, guided by experienced mentors and supported by industry leaders, the possibilities for revolutionising patient care and transforming the healthcare landscape are boundless.

In reimagining healthcare, Health Industry Hub^TM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.